View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Feb. 17 (HealthDay News) -- Injectable terbutaline should not be used for prevention or prolonged treatment of preterm labor in pregnant women because of the potential for serious maternal heart problems and death, according to a warning issued by the U.S. Food and Drug Administration. The agency also warned that oral terbutaline should not be used for prevention or any treatment of preterm labor because of similar safety concerns and the fact that it has not been shown to be effective.
The agency decided to require that a Boxed Warning and Contraindication be added to terbutaline drug labels after reviewing safety information from the medical literature and from post-marketing safety reports of terbutaline used for obstetrical indications.
Upon reviewing the new information, the FDA concluded that the risk of serious adverse events, such as increased heart rate, transient hyperglycemia, myocardial ischemia, and death, outweighs potential benefits to pregnant women receiving prolonged treatment with injectable terbutaline or acute or prolonged treatment with oral terbutaline.
"Although it may be clinically deemed appropriate based on the health care professional's judgment to administer terbutaline by injection in urgent and individual obstetrical situations in a hospital setting, the prolonged use of this drug to prevent recurrent preterm labor can result in maternal heart problems and death," according to the FDA safety announcement.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top